Prostate News Archive
16-Jun-2009
The Risk Of Renal Impairment In Hormone-Refractory Prostate Cancer Patients With Bone Metastases Treated With ... (Medical News Today)
UroToday.com- Nearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment according to a report by Dr. Oh and colleagues in the online version of Cancer.ZA is an intravenous bisphosphonate given to decrease skeletal related events in CaP patients with bone metastases. [click link for full article] Cesium-131 From IsoRay Medical (TM), Inc. Established as a Front Line Treatment for Early Stage Prostate Cancer ... (Business Wire via Yahoo! Finance)
CHICAGO----Investigators of a recent multi-institutional trial, led by principal investigator Bradley Prestidge, conclude that Cesium-131, a medical isotope used in low dose brachytherapy treatment for prostate cancer, "... has come into widespread use; and the clinical results of this trial are mature enough to be of immediate, important, practical use to practitioners." Women 'more distressed by prostate cancer' (Perth Now)
WOMEN are more distressed by prostate cancer than their male partners who are diagnosed with the disease, a study has found. EPCA-2 testing more accurate way to identify cancer in the prostate (News-Medical-Net)
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year. Prostate Cancer Conference at Mayo Clinic (KAAL Austin)
(KAAL) -- It's a type of cancer that some call the "couple disease". The Mayo Clinic in Rochester held a conference on prostate cancer, allowing men to gather information they and their loved ones may need in order to deal with the disease and life after.
Back to Prostate News Archive
